Skip to main content
Back
LYPHF logo

Luye Pharma Group Ltd.

Data quality: 100%
Overbought
LYPHF
OTC Healthcare Drug Manufacturers - General
$0.38
$0.00 (0.00%)
Mkt Cap: 1.51B
Day Range
$0.38 $0.40
52-Week Range
$0.26 $0.40
Volume
400
50D / 200D Avg
$0.38 / $0.32
Prev Close
$0.38

Quick Summary

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (631 peers)

Metric Stock Sector Median
P/E 3.2 0.2
P/B 0.1 3.0
ROE % 3.5 3.5
Net Margin % 7.8 3.8
Rev Growth 5Y % 2.3 9.7
D/E 0.7 0.2

Analyst Price Target

No analyst coverage available

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2027 $0.27
$0.25 – $0.29
 7.76B 1
FY2026 $0.19
$0.18 – $0.20
 6.96B 1

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2025-08-28 $0.01 $0.01 +18.8%
2025-03-27 $0.02 $0.00 -79.7%
2024-08-28 N/A $0.01 —
2024-04-08 $0.01 $0.01 +1.9%
2023-06-30 $0.00 $0.01 +35.3%
2023-03-29 $0.01 $0.01 +48.4%
2022-08-29 $0.02 $0.01 -34.3%
2022-03-29 $0.01 -$0.02 -266.2%

Dividend History

2 yr streak

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

Ex-Date Payment Date Amount Yield
Jun 29, 2020 Jul 31, 2020 $0.01 2.17%
Sep 09, 2019 Sep 30, 2019 $0.01 2.25%
Jun 14, 2019 Jul 18, 2019 $0.01 1.97%
Sep 06, 2018 Sep 28, 2018 $0.01 1.78%
Jun 14, 2018 Jun 29, 2018 $0.01 1.48%
Oct 04, 2017 Nov 08, 2017 $0.00 1.23%
Jun 15, 2017 Jul 18, 2017 $0.00 0.67%

Key Takeaways

Revenue grew 2.28% annually over 5 years — modest growth
Earnings declined -11.40% over the past year
ROE of 3.54% is below average
Negative free cash flow of -1.54B
P/E of 3.20 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 3.61%

Growth

Revenue Growth (5Y)
2.28%
Revenue (1Y)-1.33%
Earnings (1Y)-11.40%
FCF Growth (3Y)N/A

Quality

Return on Equity
3.54%
ROIC3.96%
Net Margin7.79%
Op. Margin21.30%

Safety

Debt / Equity
0.73
Current Ratio1.24
Interest Coverage2.30

Valuation

P/E Ratio
3.20
Forward P/E1.96
P/B Ratio0.11
EV/EBITDA5.34
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -1.33% Revenue Growth (3Y) 0.66%
Earnings Growth (1Y) -11.40% Earnings Growth (3Y) -11.67%
Revenue Growth (5Y) 2.28% Earnings Growth (5Y) -9.60%
Profitability
Revenue (TTM) 6.06B Net Income (TTM) 471.89M
ROE 3.54% ROA 1.59%
Gross Margin 66.72% Operating Margin 21.30%
Net Margin 7.79% Free Cash Flow (TTM) -1.54B
ROIC 3.96% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.73 Current Ratio 1.24
Interest Coverage 2.30
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years 2 yrs
Valuation
P/E Ratio 3.20 Forward P/E 1.96
P/B Ratio 0.11 P/S Ratio 0.25
PEG Ratio -0.23 Forward PEG N/A
EV/EBITDA 5.34 Fwd EV/EBITDA 2.21
Forward P/S 0.22 Fwd Earnings Yield 51.02%
FCF Yield -102.16%
Market Cap 1.51B Enterprise Value 6.89B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 6.06B 6.14B 5.98B 5.20B 5.54B
Net Income 471.89M 532.61M 604.81M -144.78M 706.59M
EPS (Diluted) 0.02 0.14 0.17 -0.04 0.22
Gross Profit 4.04B 4.20B 4.14B 3.40B 3.99B
Operating Income 1.29B 1.03B 1.21B 386.99M 1.42B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 29.61B 25.49B 24.25B 22.58B 20.63B
Total Liabilities 13.86B 11.96B 13.21B 13.47B 12.53B
Shareholders' Equity 14.15B 12.53B 10.18B 8.49B 7.89B
Total Debt 10.32B 8.42B 9.10B 9.49B 9.98B
Cash & Equivalents 4.94B 3.24B 2.32B 2.44B 3.87B
Current Assets 13.31B 10.70B 10.79B 10.40B 9.97B
Current Liabilities 10.77B 8.14B 9.49B 7.33B 7.23B